Market Cap: $30.48B
BI
Biogen Inc.
BIIB
NASDAQ (NASDAQ Global Select)USD
Market Cap: $30.48B
Biogen (Ticker: BIIB) is currently undergoing a significant transformation in its strategic approach, focusing on innovative therapies in the biopharmaceutical market. A Shift in Focus Moving away fro…
Biogen Inc. (Ticker: BIIB) makes headlines with its strategic acquisition of RayThera Inc., a move that underscores its commitment to expanding its neurological treatment portfolio. Recently announced…
Biogen Inc. (Ticker: BIIB) has recently achieved a significant milestone by receiving the FDA Breakthrough Therapy Designation for salanersen, an investigational treatment designed for patients with s…
Biogen Inc (Ticker: BIIB) is navigating a pivotal moment in its quest to treat Alzheimer’s disease, as the U.S. Food and Drug Administration (FDA) has delayed its review of a key treatment. The compan…
Biogen Inc. (Ticker: BIIB) is actively navigating the extended FDA review process for its Alzheimer’s treatment, LEQEMBI IQLIK, which could have significant implications for the company’s future in ne…
Biogen's recent acquisition of felzartamab from TJ Biopharma marks a significant milestone in its strategic expansion within the immunology sector, particularly in the Greater China region. The deal,…
Biogen's SPINRAZA™ High Dose Regimen Approval Marks a Milestone for SMA Treatment In a significant development for the spinal muscular atrophy (SMA) community, Biogen receives FDA approval for the Hig…
Analyst Chorus Narrows on Biogen's Strategic Crossroads Pipeline, Regulation and Commercial Execution Take Center Stage Biogen (NASDAQ:BIIB) is facing intensified scrutiny as 21 financial analysts pub…
Biotech spotlight: Biogen’s earnings set to frame sector conversation Biogen is reporting quarterly results on Friday morning and the company’s update is taking on outsized importance for the biotech…
Empowering Lupus Patients Through Innovative Engagement Initiatives Proximity Health Solutions, in collaboration with Biogen, gains recognition for its groundbreaking initiative "Better Together: Shar…
Biogen's Strategic Positioning Amidst Analyst Scrutiny In the latest quarterly evaluation, Biogen garners attention from nine analysts, each presenting a mix of ratings that reflect a spectrum of conf…
Johnson & Johnson's Advancements in Lupus Treatment: A Step Toward Innovative Solutions Johnson & Johnson (NYSE: JNJ) makes headlines with the topline results from its Phase 2b JASMINE study, which ev…
Biogen's Position in the Evolving Autoimmune Disease Landscape Biogen faces a critical juncture in the biopharmaceutical industry as it navigates the complexities of autoimmune disease treatment. With…
Biogen's Strategic Focus on Innovation in Neurodegenerative Diseases Biogen, a leading biotechnology company, remains at the forefront of research and development in neurodegenerative diseases, a sect…
### Biogen’s Strategic Positioning in the Evolving Pharmaceutical Landscape Biogen, a leader in neuroscience, is navigating the complexities of the pharmaceutical industry amidst a landscape character…
Biogen Faces Growing Bearish Sentiment Amid Increased Short Interest Biogen Inc. experiences a significant uptick in short interest, which rises by 10.35% since the last reporting period. Currently, 6…
Biogen Faces Rising Bearish Sentiment Amid Increased Short Interest Biogen Inc. is currently experiencing a significant uptick in short interest, which has risen by 10.35% since the last report. As of…
Breakthrough Findings in Alzheimer's Treatment: LEQEMBI's Long-Term Impact At the recent 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference, Biogen Inc. and Eisai Co., Ltd. unveil promising…
Biogen and Eisai Pursue New Administration Route for Alzheimer’s Treatment Biogen Inc. and its partner Eisai Co., Ltd. take a significant step forward in the treatment of Alzheimer’s disease with the…
Biogen's Position in Alzheimer's Research Strengthened Amid Competitor Setbacks Biogen Inc. is capitalizing on the recent setbacks faced by competitors in the Alzheimer's treatment space, particularly…
Strategic Insights into Biogen's Market Dynamics Recent trends in Biogen's trading activity reveal a notable shift in market sentiment, particularly among high-profile investors. Analysis from Benzing…
Biogen's Strategic Innovations: A Beacon in Neurology Biogen is currently making significant strides in the biotechnology sector, particularly in the field of neurology. The company focuses on develop…
FDA Leadership Shakeup: Implications for Drug Safety and Regulatory Integrity The recent resignation of George Tidmarsh, head of the FDA's drug center, raises significant questions about the integrity…
Biogen's Strategic Positioning Amid Market Dynamics Biogen remains at the forefront of the biotechnology sector, particularly focusing on the treatment of neurological diseases. As the company navigat…
Biogen's Upcoming Earnings Report: A Focus on Innovation and Pipeline Development As Biogen prepares to release its quarterly earnings on October 30, 2025, the biotechnology company stands at a pivota…
Ionis Pharmaceuticals Poised for Key Earnings Report Amidst Promising Developments Ionis Pharmaceuticals stands at a pivotal moment as it prepares to announce its quarterly earnings on October 29, 202…
Biogen Navigates Challenges with Focus on Neurological Innovations Biogen, a prominent player in the biotechnology sector, prepares to unveil its quarterly earnings on October 30, 2025, amidst a compl…
Biogen Expands Immunology Portfolio with Vanqua Bio Licensing Agreement Biogen Inc. has recently forged a significant licensing agreement with Vanqua Bio, granting the company exclusive worldwide righ…
Zai Lab's Strategic Shift: Navigating Complexities in Biotech Agreements Zai Lab, a prominent player in the biotechnology sector, recently announces a significant agreement to sell certain rights to i…
Biogen's Strategic Positioning in the Neurology Drug Market Biogen's recent evaluations from seven analysts reveal a complex landscape for the biotechnology company as it endeavors to advance its trea…
Adicet Bio's Promising Clinical Trial Signals Hope for Autoimmune Disease Treatments Adicet Bio Inc. announces noteworthy early results from its Phase 1 clinical trial of ADI-001, a therapeutic candid…
Adicet Bio Navigates Clinical Success Amidst Financial Concerns Adicet Bio Inc. announces a direct offering of $80 million, a strategic financial move that raises eyebrows amid promising early safety…
Biogen Leverages Market Sentiment Amid Economic Concerns Biogen finds itself navigating through a complex economic landscape as Wall Street experiences modest gains despite a government shutdown and d…
Biogen's Strategic Focus Amid Economic Uncertainty Biogen, a leader in biotechnology, navigates a challenging economic landscape characterized by stagnant job growth and elevated unemployment rates. A…
Pharmaceutical Landscape Shifts as Tariff Implementation Looms As the pharmaceutical industry braces for the implementation of a sweeping 100% tariff on imported medications beginning October 1, compa…
Biogen Partners with NAF to Raise Awareness for Friedreich Ataxia In a significant move to enhance awareness and understanding of Friedreich ataxia (FA), Biogen Inc. collaborates with the National Ata…
Biogen's Strategic Position in the Biopharmaceutical Landscape Biogen navigates a complex biopharmaceutical environment, characterized by a diverse set of analyst evaluations that range from optimisti…
Ionis Pharmaceuticals: Navigating the Complex Landscape of Biotechnology Ionis Pharmaceuticals is currently at the center of analytical scrutiny, with 22 expert ratings highlighting a diverse spectrum…
Navigating Innovation and Uncertainty: Biogen's Position in the Biopharmaceutical Landscape Biogen is currently at a pivotal point in the biopharmaceutical industry, with its innovative focus on treat…
Biogen Expands Neurological Portfolio with Alcyone Therapeutics Acquisition Biogen Inc. recently announces its strategic acquisition of Alcyone Therapeutics, a Massachusetts-based biotechnology firm,…
Biogen's Commitment to Neurodegenerative Disease Research Shines in Recent Developments Biogen is making significant strides in the field of neurodegenerative disease research, particularly through it…
FDA Mandates Enhanced Monitoring for Alzheimer’s Treatment with Leqembi In a significant development for Alzheimer’s treatment, the U.S. Food and Drug Administration (FDA) mandates that patients recei…
Prothena Advances Alzheimer’s Research with Promising ASCENT Clinical Trial Results Prothena Corporation plc has made significant strides in the field of Alzheimer’s disease (AD) research with the rec…
Johnson & Johnson Expands Manufacturing Footprint Amid Regulatory Changes In a significant move for the pharmaceutical sector, Johnson & Johnson (JNJ) announces a $2 billion investment aimed at enhanc…
Biogen's Bullish Technical Formation Signals Potential Rebound Biogen Inc. finds itself in a pivotal moment as it attempts a breakout from a key bullish formation, specifically a cup-and-handle patter…
Biogen's Technical Rebound: A Potential Turning Point Biogen Inc. is currently navigating a pivotal moment in its market trajectory as it attempts to establish a bullish breakout from a significant te…
Eli Lilly's Strategic Moves in Diabetes Care Present Competitive Landscape for Biogen Eli Lilly and Co. recently announces a substantial increase in the list price of its diabetes and weight-loss medi…
Biogen's Strategic Outlook on Alzheimer’s Treatment Innovations Biogen Inc. CEO Chris Viehbacher sheds light on the potential implications of a successful Alzheimer’s trial for Novo Nordisk A/S’s weig…
Innovative Synergies in Alzheimer’s Treatment: Biogen's Strategic Outlook Biogen Inc. underscores its commitment to advancing Alzheimer’s treatment through innovative approaches and potential collabor…
Analysts Present Mixed Views on Biogen’s Future Amid Industry Challenges In recent months, the biotechnology sector has witnessed notable fluctuations, and Biogen Inc. finds itself at the center of th…